Juvmo (tavapadon)

AbbVie has published no price statement. Benzinga reported on 28 September 2026 that a William Blair analyst gave a list price of $4,900 per 30-day supply, or $58,800 per year, and the public meeting slides of the Institute for Clinical and Economic Review (ICER) of 1 October 2026 list a reported wholesale acquisition cost of $58,800 per year. The ICER evidence report evaluated tavapadon at a placeholder price of $15,000 per year, and ICER's published budget impact results use that placeholder. In early Parkinson's disease, tavapadon cost $26,500 more than levodopa and produced 0.015 fewer quality-adjusted life years (QALYs). As an adjunct to levodopa, it cost $16,900 more than a dopamine agonist market basket for 0.010 additional QALYs, or $1.7 million per QALY gained. At the placeholder price, 46% of the first-line candidate population and 59% of the add-on candidate population could be treated before reaching ICER's potential budget impact threshold of $821 million.